Pharmacokinetic Profiles
1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
NeuroDawn PharmaceuticalChina - Nanjing
1 program1
sequentially single use of repaglinide, warfarin and omeprazole or combined with Y-3Phase 11 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2025
2026
NeuroDawn Pharmaceuticalsequentially single use of repaglinide, warfarin and omeprazole or combined with Y-3
Clinical Trials (1)
Total enrollment: 24 patients across 1 trials
NCT07068841NeuroDawn Pharmaceuticalsequentially single use of repaglinide, warfarin and omeprazole or combined with Y-3
Pharmacokinetic Effect of Y-3 on Repaglinide，Warfarin and Omeprazole in Healthy Participants
Start: May 2025Est. completion: Jun 202524 patients
Phase 1Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.